Adrian Lee, Director of the Institute for Precision Medicine at UPMC, Professor at UPMC Hillman Cancer Center, and at the University of Pittsburgh, shared a post on LinkedIn:
“Great discussion this morning at PMWC2026 moderating our panel on Serial ctDNA-guided therapy switching: SERENA-6 and beyond.
Together with Pedram Razavi, Minetta Liu, Christian Rolfo, Dr.hc Rolfo, and Emre B., we explored how emerging ctDNA signals – particularly ESR1 mutations – may allow therapy to be switched before clinical progression, potentially reshaping how we monitor and treat cancer.
The conversation spanned trial design, regulatory endpoints, and the growing role of AI in enabling physicians to make decisions. If the field continues to move this quickly, continuous molecular surveillance may soon become routine oncology care.
Thrilling discussion and an exciting glimpse of where precision oncology is heading.”
More posts featuring Adrian Lee.